MAPT and chronic kidney disease: Moreover, since comorbidities such as chronic kidney disease are reported to have a non-negligible impact on the interpretation of plasma p-tau181 and p-tau217 levels [16], further studies exploring their potential impact on tau PET biomarkers are warranted.